학술논문
전자자료 공정이용 안내
우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.
공정이용 지침
- 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
- 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
- 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
- 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
- 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
- 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
- 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
- 상업적·영리적 목적으로 자료를 전송·복제·활용
- ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
- EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
- 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
- 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
- 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문'
에서 검색결과 392건 | 목록
1~20
Academic Journal
Jorge Leschot Gatica; Eduardo Guzman Muñoz; Miguel Alarcón-Rivera; Marco Montoya-Ramos Montoya Ramos; Lytton Leiva-Díaz
Retos: Nuevas Tendencias en Educación Física, Deportes y Recreación, Vol 69 (2025)
Academic Journal
DeJongh J; LAP&P Consultants BV, Leiden, The Netherlands.; Cadogan E; Bioscience, Early Oncology R&D, AstraZeneca, Cambridge, UK.; Davies M; DMPK, Early Oncology R&D, AstraZeneca, Cambridge, UK.; Ramos-Montoya A; Bioscience, Early Oncology R&D, AstraZeneca, Cambridge, UK.; Smith A; DMPK, Early Oncology R&D, AstraZeneca, Cambridge, UK.; van Steeg T; LAP&P Consultants BV, Leiden, The Netherlands.; Richards R; DMPK, Early Oncology R&D, AstraZeneca, Waltham, MA, USA. Ryan.Richards@astrazeneca.com.
Publisher: Springer Country of Publication: United States NLM ID: 101096520 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-8744 (Electronic) Linking ISSN: 1567567X NLM ISO Abbreviation: J Pharmacokinet Pharmacodyn Subsets: MEDLINE
Academic Journal
Sharan K. Bagal; Peter C. Astles; Coura Diène; Argyrides Argyrou; Claire Crafter; Doyle J. Cassar; Charlene Fallan; Andreas Hock; Thomas Jones; Kevin Moreau; Gillian M. Lamont; Scott Lamont; Chrysiis Michaloglou; Martin J. Packer; Andy Pike; Antonio Ramos-Montoya; James S. Scott; Joseph Shaw; Ziyanda Shologu
Journal of Medicinal Chemistry. 67:11732-11750
Conference
Gauffin L; Montoyo-Pujol Y; Delgado-García S; Galiana H; Martin T; Ramos-Montoya A; Ponce J; Castellon-Molla E; Niveiro M; Peiro G
LABORATORY INVESTIGATION
r-FISABIO. Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Academic Journal
Pensar en Movimiento, Vol 23, Iss 2 (2025)
Academic Journal
Scott JS; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Evans L; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Astles PC; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Argyrou A; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.; Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Beattie D; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Braybrooke EL; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Cassar DJ; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Crafter C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Diène C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Fairley G; Oncology R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.; Fallan C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Fraser G; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Galeano-Dalmau N; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Hammond TG; Safety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.; Hock AK; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.; Jones T; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.; Komen J; Safety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.; Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Michaloglou C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Niedbala MJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.; Ramos-Montoya A; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Rodrigo-Brenni MC; Safety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.; Packer MJ; Oncology R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.; Pearson S; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Pike A; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Schade M; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Shaw J; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.; Shologu Z; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.; Steward O; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Academic Journal
Yoel G. Montoyo-Pujol; José J. Ponce; Silvia Delgado-García; Tina A. Martín; Hortensia Ballester; Elena Castellón-Molla; Angela Ramos-Montoya; Inmaculada Lozano-Cubo; J. Miguel Sempere-Ortells; Gloria Peiró
Cancer Cell International, Vol 24, Iss 1, Pp 1-17 (2024)
Report
Bizzaro F; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.; Fuso Nerini I; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.; Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.; Taylor MA; Early Oncology, AstraZeneca, Cambridge, UK.; Anastasia A; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.; Russo M; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.; Damia G; Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.; Guffanti F; Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.; Guana F; Laboratory of Cancer Genomics, Fondazione Edo ed Elvo Tempia Valenta, Biella, Italy.; Ostano P; Laboratory of Cancer Genomics, Fondazione Edo ed Elvo Tempia Valenta, Biella, Italy.; Minoli L; Department of Veterinary Medicine, University of Milan, Milan, Italy.; Hattersley MM; Early Oncology, AstraZeneca, Boston, USA.; Arnold S; Early Oncology, AstraZeneca, Cambridge, UK.; Ramos-Montoya A; Early Oncology, AstraZeneca, Cambridge, UK.; Williamson SC; Early Oncology, AstraZeneca, Cambridge, UK.; Galbiati A; Early Oncology, AstraZeneca, Cambridge, UK.; Urosevic J; Early Oncology, AstraZeneca, Cambridge, UK.; Leo E; Early Oncology, AstraZeneca, Cambridge, UK.; Cavallaro U; Unit of Gynecological Oncology Research, Istituto Europeo di Oncologia IRCCS, Milan, Italy.; Ghilardi C; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.; Barry ST; Early Oncology, AstraZeneca, Cambridge, UK.; Bani MR; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy. mariarosa.bani@marionegri.it.; Giavazzi R; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.
Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE
Academic Journal
Claire Crafter; Antonio Ramos-Montoya; Chrysiis Michaloglou; Ziyanda Shologu; Nuria Galeano-Dalmau; Gemma Hardman Fowler; Ana Quiroga; Pablo Morentin-Gutierrez; Andy Pike; Laura Evans; James S. Scott; Michael Niedbala
Cancer Research. 85:4758-4758
Academic Journal
Pablo Morentin Gutierrez; Ana Quiroga Campano; Antonio Ramos Montoya; Claire Crafter; Chrysiis Michaloglou; Aaron Smith; Nuria Galeano Dalmau; Jamie Scott; Michael Niedbala
Cancer Research. 85:4755-4755
Academic Journal
Revista Psicológica Herediana. 15:54-60
Academic Journal
Ross-Adams, H; Lamb, AD; Dunning, MJ; Halim, S; Lindberg, J; Massie, CM; Egevad, LA; Russell, R; Ramos-Montoya, A; Vowler, SL
EBIOMEDICINE. 2(9):1133-1144
Academic Journal
Fok JHL; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.; Ramos-Montoya A; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.; Vazquez-Chantada M; Mechanistic Biology and Profiling, Discovery Sciences, Oncology R&D, AstraZeneca, Cambridge, UK.; Wijnhoven PWG; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.; Follia V; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.; James N; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.; Farrington PM; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.; Karmokar A; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.; Willis SE; Translational Science, Oncology R&D, AstraZeneca, Cambridge, UK.; Cairns J; Quantitative Biology, Discovery Science, Oncology R&D, AstraZeneca, Cambridge, UK.; Nikkilä J; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.; Beattie D; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK.; Lamont GM; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK.; Finlay MRV; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK.; Wilson J; DMPK, Oncology R&D, AstraZeneca, Cambridge, UK.; Smith A; DMPK, Oncology R&D, AstraZeneca, Cambridge, UK.; O'Connor LO; Translational Science, Oncology R&D, AstraZeneca, Cambridge, UK.; Ling S; Mechanistic Biology and Profiling, Discovery Sciences, Oncology R&D, AstraZeneca, Cambridge, UK.; Fawell SE; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.; O'Connor MJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.; Hollingsworth SJ; Oncology Business Unit, AstraZeneca, Cambridge, UK.; Dean E; Oncology Translational Medicine Unit, Early Clinical Development, Oncology R&D, AstraZeneca, Cambridge, UK.; Goldberg FW; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK.; Davies BR; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK.; Cadogan EB; Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK. elaine.cadogan@astrazeneca.com.
Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Academic Journal
Frederick W. Goldberg; Attilla K. T. Ting; David Beattie; Gillian M. Lamont; Charlene Fallan; M. Raymond V. Finlay; Beth Williamson; Marianne Schimpl; Alexander R. Harmer; Oladipupo B. Adeyemi; Pär Nordell; Anna S. Cronin; Mercedes Vazquez-Chantada; Derek Barratt; Antonio Ramos-Montoya; Elaine B. Cadogan; Barry R. Davies
ACS Medicinal Chemistry Letters. 13:1295-1301
Academic Journal
Alessia Anastasia; Giulia Dellavedova; Antonio Ramos-Montoya; Neil James; Giovanna Chiorino; Massimo Russo; Hana Baakza; Joanne Wilson; Carmen Ghilardi; Elaine B. Cadogan; Raffaella Giavazzi; Maria Rosa Bani
Molecular Cancer Therapeutics. 21:555-567
Academic Journal
Kyoko Nakamura; Ankur Karmokar; Paul M. Farrington; Neil H. James; Antonio Ramos-Montoya; Susan J. Bickerton; Gareth D. Hughes; Timothy M. Illidge; Elaine B. Cadogan; Barry R. Davies; Simon J. Dovedi; Viia Valge-Archer
Clin Cancer Res
Nakamura, K, Karmokar, A, Farrington, P M, James, N H,Ramos -Montoya , A, Bickerton, S J, Hughes, G D, Illidge, T M, Cadogan, E B, Davies, B R, Dovedi, S J & Valge-Archer, V 2021, 'Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 15, pp. 4353-4366. https://doi.org/10.1158/1078-0432.CCR-20-3701
Nakamura, K, Karmokar, A, Farrington, P M, James, N H,
검색 결과 제한하기
제한된 항목
[검색어] Ramos-Montoya, A.
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어